Hello, my name is Vinod Dhakal and I'm an associate professor of medicine at Medical College of Wisconsin. During this IAHA meeting, we are presenting a poster which is a phase 1b2 dose escalation study of sonorotoclax with dexamethasone in patients with relapsed retractive multiple myeloma with translocation 1114. BCL2 inhibitors have shown activity in multiple myeloma, however, no BCL2 inhibitors have been approved for multiple myeloma. Sonorotoclax is a novel BCL2 inhibitor which appeared to be more potent than venetoclax in the preclinical studies as well as with low clearance. And in this study we tested sonorotoclax at different dose levels at the dose escalation fashion with dexamethasone in patients with relapsed refractive multiple myeloma and translocation 1114. In this poster we are presenting the data on maximum dose that we have tested so far which is 640 mg of sonorotoclax with dexamethasone in patients. The median lines of therapy was 4. 70% of patients were triple class exposed and refractory and that means the patients are pretty heavily treated. The patients are given daily sonorotoclax with weekly dexamethasone at 40 mg with daily sonorotoclax of 640 mg. Now in terms of safety we did not see any dose limiting toxicities at that dose. The grade 3-4 treatment adverse events was happened in 10 patients and serious adverse events happened in 6 patients. Otherwise the remaining side effect profile is pretty manageable and pretty tolerable. Most of the cytopenias at grade 1 and 2. In terms of efficacy we saw an overall response rate of 75% with a very good and partial response rates of 50% and complete response and better rate of 21%. This study is ongoing with the combination not only with dexamethasone but also with carfilzomib, darachromab and other combinations and we are looking forward to have this important compound in this particular subset of patients.
HealthTree • June 24, 2024